title: Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
abstract: Imatinib mesylate (Gleevec, Glivec; Novartis, Basel, Switzerland) is a specific tyrosine kinase inhibitor that has become the gold-standard treatment for patients with chronic myeloid leukemia. Several tyrosine kinases inhibited by imatinib are expressed in the kidney, and although the drug is usually well tolerated, several cases of acute renal failure were reported. We describe for the first time a case of a patient treated by imatinib for chronic myeloid leukemia who developed partial Fanconi syndrome with mild renal failure, which leads to a discussion of the pathophysiological characteristics of imatinib-induced renal toxicity. Patients on long-term imatinib treatment should be monitored for renal failure, as well as proximal tubule dysfunction, including hypophosphatemia.
authors.affiliation: AP-HP, Assistance Publique-Hôpitaux de Paris, Department of Nephrology and Dialysis, Tenon Hospital, Paris, France. helene.francois@tnn.aphp.fr
authors.forename: Helene
authors.initials: H
authors.lastname: François
authors.forename: Paul
authors.initials: P
authors.lastname: Coppo
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Hayman
authors.forename: Bruno
authors.initials: B
authors.lastname: Fouqueray
authors.forename: Béatrice
authors.initials: B
authors.lastname: Mougenot
authors.forename: Pierre
authors.initials: P
authors.lastname: Ronco
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D005198:Fanconi Syndrome / Q000139:chemically induced* / Q000503:physiopathology / Q000652:urine; D005260:Female; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010710:Phosphates / Q000652:urine*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010710:Phosphates; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases